Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 2/8/23 → 1/8/25 |
Funding
- IDEAYA Biosciences: $31,268.00
22-MULTI-56-IB-PMC (IDE397) An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors
- Villano, PhD, John (PI)